Parsemus Foundation Press Information
About the Parsemus Foundation
The Parsemus Foundation works to create meaningful improvements in human and animal health and welfare by advancing innovative and neglected medical research. The foundation supports proof-of-concept studies and then seeks to raise awareness of results, to ensure that they change treatment practice rather than disappear into the scientific literature. Many of the studies the foundation supports involve low-cost approaches that are not under patent, and are thus unlikely to be pursued by pharmaceutical companies due to limited profit potential.
The Parsemus Foundation’s main focus has been developing Vasalgel as a non-hormonal male contraceptive. The foundation has partnered with NEXT Life Sciences to complete development of the product and bring it to market. For information on Vasalgel, please contact NEXT Life Sciences.
For information on the development of non-hormonal male contraceptives, visit the Male Contraceptive Initiative.
The foundation also works on pet contraception, including calcium chloride nonsurgical neuter and hormone-sparing sterilization options; noninvasive treatment for benign prostatic hyperplasia (enlarged prostate); and serves as a resource for information on over-used medical procedures, innovative breast cancer treatment, aldosterone and hearing, and the effect of testosterone and DHA on Alzheimer’s disease.
A major effort since 2020 has been addressing the need for research on COVID-19 treatments. The Parsemus Foundation supported clinical studies on the effectiveness of existing medications to treat COVID infection, including enrollment support for the University of Minnesota’s COVID-Out trial.
For media coverage of our projects, please contact us at firstname.lastname@example.org
COVID-OUT Clinical Trial Results Announced!
The key finding: if started within 4 days of COVID symptoms, the widely available diabetes drug metformin reduced serious outcomes by more than half.
Background: The COVID-OUT clinical trial was aimed at understanding if safe, commonly available medications may treat COVID-19 symptoms and those of long COVID. The study examined the medications metformin, ivermectin, and fluvoxamine, which are known to decrease inflammatory proteins (cytokines) in the body. They also appear to possibly stop the proteins inside cells that help viruses reproduce and spread. This rigorous randomized, controlled clinical trial was conducted by the University of Minnesota under the direction of Dr. Carolyn Bramante.
Funders: The Parsemus Foundation provided pilot funding and enrollment support to the University of Minnesota. Additional major funders include the University of Minnesota Clinical Translational Science Institute, the Rainwater Foundation, FastGrants, and UnitedHealth Group Research and Development.
- Parsemus Foundation Press Release (English, Spanish, Portuguese)
- University of Minnesota COVID-OUT Press Release
- Parsemus Foundation COVID-OUT webpage
- New England Journal of Medicine Publication
- KARE 11 News coverage
- Northwestern Medicine release
- University of Colorado release
- Parsemus Foundation video files English, Spanish, Portuguese
Image Files, Videos, and Printable Materials
Parsemus Foundation Logo
Vector-based logo in full color
Vector-based logo in silhouette
Executive And Associate Headshots
Elaine Lissner, Founder and Trustee, Parsemus Foundation and Revolution Contraceptives, LLC
Linda Brent, PhD, MBA, Executive Director, Parsemus Foundation